Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Transthyretin amyloidosis (ATTR-CM) occurs when the liver produces faulty transthyretin (TTR) proteins. Clumps of these abnormal proteins (called fibrils) build up in the heart's main pumping chamber.Friday, BridgeBio Pharma Inc. (NASDAQ:BBIO) presented additional data from an analysis of its Phase 3 ATTRibute-CM and open-label extension study of acoramidis in ATTR-CM at the European Society of Cardiology (ESC) 2024.
周五，阿里拉姆制药公司（纳斯达克: BBIO）在欧洲心脏学会（ESC）2024年的阿特里布特-Cm的第三期ATTRibute-Cm和开放标签扩展研究中公布了额外的数据分析结果。
The data included change from baseline in serum TTR levels in participants receiving acoramidis versus those receiving tafamidis in the placebo group in ATTRibute-CM at Month 30, as well as serum TTR levels in patients who transitioned from placebo and tafamidis to acoramidis.
该数据包括在参与者接受acoramidis与在ATTRibute-Cm中接受tafamidis的安慰剂组之间的血清TTR水平变化（基线）在30个月时期的数据，以及从安慰剂和tafamidis转换到acoramidis的患者的血清TTR水平。
Also Read: Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles.
此外阿里拉姆制药股票在详细介绍一个伴有心脏肌肉僵硬的病症的Vutrisiran数据后出现了下跌。
Transthyretin amyloidosis (ATTR-CM) occurs when the liver produces faulty transthyretin (TTR) proteins. Clumps of these abnormal proteins (called fibrils) build up in the heart's main pumping chamber.
当肝脏产生有缺陷的甲状腺转运蛋白（TTR）蛋白质时，淀粉样蛋白性甲状腺转运蛋白（ATTR-CM）即出现。这些异常蛋白（称为纤维）的团块在心脏的主要泵室中堆积。
In participants who switched from Pfizer Inc's (NYSE:PFE) Vyndaqel (tafamidis) and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum TTR at Month 1 of the OLE (n=21, p=0.01) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18, p=0.01).
在从辉瑞（纽交所:PFE）的Vyndaqel（tafamidis）和安慰剂转换到阿特里布特-Cm研究的acoramidis开放标签扩展（OLE）中的参与者中，OLE的第1个月血清TTR平均增加了3.0mg/dL（n = 21，p = 0.01），OLE的第6个月血清TTR平均增加了3.4mg/dL（n = 18，p = 0.01）。
BridgeBio submitted a marketing application to the FDA, which has been accepted with a PDUFA action date of November 29, and a marketing application to the European Medicines Agency, with a decision expected in 2025.
BridgeBio已向美国食品药品监督管理局（FDA）提交了一份营销申请，并在2024年11月29日获得了审评报告，还向欧洲药品管理局提交了一份营销申请，预计在2025年做出决定。
BridgeBio has granted Bayer AG (OTC:BAYRY) exclusive rights to commercialize acoramidis for ATTR-CM in Europe.
BridgeBio已授予拜耳（adr）在欧洲商业化acoramidis用于ATTR-Cm的独家权利。
Price Action: BBIO stock is up 12.50% at $27.69 at the last check on Friday.
市场表现:BBIO股票在周五最后一次检查时上涨12.50%，报27.69美元。
- Lockheed Martin Resumes Delivery Of F-35 Jets, But US Government To Withhold Some Payment Putting Profit Margins Under Pressure.
- 洛克希德马丁恢复交付F-35战机，但美国政府将暂停部分支付，使得利润率面临压力。